CL2022003380A1 - Péptidos restringidos por a*03, uso en inmunoterapia contra cáncer y métodos relacionados (solicitud divisional de 202003371) - Google Patents
Péptidos restringidos por a*03, uso en inmunoterapia contra cáncer y métodos relacionados (solicitud divisional de 202003371)Info
- Publication number
- CL2022003380A1 CL2022003380A1 CL2022003380A CL2022003380A CL2022003380A1 CL 2022003380 A1 CL2022003380 A1 CL 2022003380A1 CL 2022003380 A CL2022003380 A CL 2022003380A CL 2022003380 A CL2022003380 A CL 2022003380A CL 2022003380 A1 CL2022003380 A1 CL 2022003380A1
- Authority
- CL
- Chile
- Prior art keywords
- peptides
- relates
- present
- related methods
- cancer immunotherapy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a péptidos, proteínas, ácidos nucleicos y células destinados a la utilización en métodos inmunoterapéuticos. En particular, la presente invención se refiere a la inmunoterapia contra el cáncer. La presente invención se refiere asimismo a epítopos peptídicos para linfocitos T asociados a tumores, solos o en combinación con otros péptidos asociados a tumores que, por ejemplo, pueden servir como principios activos farmacéuticos en composiciones vacunales destinadas a estimular respuestas inmunitarias antitumorales, o a estimular ex vivo linfocitos T que después serán transferidos a los pacientes. Los péptidos unidos a moléculas del complejo mayor de histocompatibilidad (MHC), o los péptidos como tales, también pueden ser dianas de anticuerpos, de receptores de linfocitos T solubles, y de otras moléculas de unión.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692348P | 2018-06-29 | 2018-06-29 | |
| DE102018115865.3A DE102018115865A1 (de) | 2018-06-29 | 2018-06-29 | A*03-restringierte Peptide zur Verwendung in der Immuntherapie gegen Krebs und verwandte Verfahren |
| DE102018116584 | 2018-07-09 | ||
| US16/030,725 US10925947B2 (en) | 2018-06-29 | 2018-07-09 | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022003380A1 true CL2022003380A1 (es) | 2023-06-02 |
Family
ID=67070807
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003371A CL2020003371A1 (es) | 2018-06-29 | 2020-12-23 | Péptidos restringidos por a*03 para el uso en la inmunoterapia contra el cáncer y métodos relacionados |
| CL2022003380A CL2022003380A1 (es) | 2018-06-29 | 2022-11-30 | Péptidos restringidos por a*03, uso en inmunoterapia contra cáncer y métodos relacionados (solicitud divisional de 202003371) |
| CL2022003382A CL2022003382A1 (es) | 2018-06-29 | 2022-11-30 | Péptidos restringidos por a*03, uso en inmunoterapia contra cáncer y métodos relacionados (solicitud divisional de 202003371) |
| CL2022003381A CL2022003381A1 (es) | 2018-06-29 | 2022-11-30 | Péptidos restringidos por a*03, uso en inmunoterapia contra cáncer y métodos relacionados (solicitud divisional de 202003371) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020003371A CL2020003371A1 (es) | 2018-06-29 | 2020-12-23 | Péptidos restringidos por a*03 para el uso en la inmunoterapia contra el cáncer y métodos relacionados |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022003382A CL2022003382A1 (es) | 2018-06-29 | 2022-11-30 | Péptidos restringidos por a*03, uso en inmunoterapia contra cáncer y métodos relacionados (solicitud divisional de 202003371) |
| CL2022003381A CL2022003381A1 (es) | 2018-06-29 | 2022-11-30 | Péptidos restringidos por a*03, uso en inmunoterapia contra cáncer y métodos relacionados (solicitud divisional de 202003371) |
Country Status (19)
| Country | Link |
|---|---|
| US (12) | US10925947B2 (es) |
| EP (1) | EP3813873A1 (es) |
| JP (2) | JP7579145B2 (es) |
| KR (1) | KR20210025534A (es) |
| CN (2) | CN112399853A (es) |
| AU (1) | AU2019294731A1 (es) |
| BR (1) | BR112020022250A2 (es) |
| CA (1) | CA3097698A1 (es) |
| CL (4) | CL2020003371A1 (es) |
| CO (1) | CO2020013659A2 (es) |
| CR (1) | CR20200632A (es) |
| IL (1) | IL279843A (es) |
| MA (1) | MA53004A (es) |
| MX (1) | MX2020012257A (es) |
| PE (1) | PE20211499A1 (es) |
| PH (1) | PH12020552013A1 (es) |
| SG (1) | SG11202009659XA (es) |
| TW (1) | TW202019462A (es) |
| WO (1) | WO2020002063A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111533797A (zh) * | 2017-04-10 | 2020-08-14 | 伊玛提克斯生物技术有限公司 | 用于癌症免疫治疗的肽及其肽组合物 |
| KR20220167288A (ko) * | 2020-04-14 | 2022-12-20 | 유니버시떼 드 몬트리얼 | 급성 골수성 백혈병(aml)에 대한 신규한 종양-특이적 항원 및 이의 용도 |
| CN120712104A (zh) * | 2022-10-14 | 2025-09-26 | 广东天科雅生物医药科技有限公司 | 针对神经胶质瘤的肽疫苗及其用途 |
| WO2025040598A2 (en) * | 2023-08-18 | 2025-02-27 | Immatics Biotechnologies Gmbh | Peptides displayed by mhc for use in immunotherapy against different types of cancer |
| CN119530167A (zh) * | 2024-08-30 | 2025-02-28 | 江苏亲科生物研究中心有限公司 | Scgb1d4单克隆抗体及其试剂盒的制备方法和用途 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IL59007A (en) | 1978-12-22 | 1983-11-30 | Biogen Nv | Recombinant dna molecules coding for polypeptides displaying hepatitis b virus antigenicity,method of their production and compositions containing the same |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4897445A (en) | 1986-06-27 | 1990-01-30 | The Administrators Of The Tulane Educational Fund | Method for synthesizing a peptide containing a non-peptide bond |
| US9340577B2 (en) | 1992-08-07 | 2016-05-17 | Epimmune Inc. | HLA binding motifs and peptides and their uses |
| DE69420137T2 (de) | 1993-06-03 | 1999-12-23 | Therapeutic Antibodies, Inc. | Herstellung von antikörperfragmenten |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| US5807978A (en) | 1995-06-07 | 1998-09-15 | Kokolus; William J. | Immunogenic peptides of prostate specific antigen |
| ATE244300T1 (de) | 1996-01-17 | 2003-07-15 | Imp College Innovations Ltd | Immunotherapie mit verwendung von zytotoxischen t lymphozyten (ctl) |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| AUPO500997A0 (en) * | 1997-02-07 | 1997-03-06 | Macquarie Research Limited | Diagnosis of disease using tears |
| US6406705B1 (en) | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| US20070020327A1 (en) * | 1998-11-10 | 2007-01-25 | John Fikes | Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions |
| US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
| CA2404489A1 (en) | 2000-03-27 | 2001-10-04 | Technion Research And Development Foundation Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
| CN101712721A (zh) | 2000-06-05 | 2010-05-26 | 阿尔托生物科学有限公司 | T细胞受体融合物及共轭物以及其使用方法 |
| US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
| AU2003216341A1 (en) | 2002-02-20 | 2003-09-09 | Dyax Corporation | Mhc-peptide complex binding ligands |
| EP1549748B1 (en) | 2002-10-09 | 2014-10-01 | Immunocore Ltd. | Single chain recombinant t cell receptors |
| DK1558643T3 (da) | 2002-11-09 | 2009-09-07 | Immunocore Ltd | Cellereceptorpr sentation |
| AU2003296330A1 (en) * | 2002-12-10 | 2004-06-30 | Epimmune Inc. | Hla-a1, a2 -a3,-a24,-b7,and -b44 tumor associated antigen peptides and compositions |
| GB0304068D0 (en) | 2003-02-22 | 2003-03-26 | Avidex Ltd | Substances |
| ATE461215T1 (de) | 2005-09-05 | 2010-04-15 | Immatics Biotechnologies Gmbh | Tumor-assoziierte peptide, welche an unterschiedliche menschliche leukozytenantigene der klasse ii binden |
| WO2008118017A2 (en) * | 2007-03-26 | 2008-10-02 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Prame derived peptides and immunogenic compositions comprising these |
| US7867483B2 (en) * | 2007-10-18 | 2011-01-11 | Bn Immunotherapeutics, Inc. | Use of MVA to treat prostate cancer |
| US20090263574A1 (en) | 2008-04-21 | 2009-10-22 | Quinn Daniel E | Method of restoring an article |
| US9840695B2 (en) | 2009-04-28 | 2017-12-12 | Agriculture Victoria Services Pty Ltd | Plant technology |
| US9023802B2 (en) | 2009-12-14 | 2015-05-05 | Immatics Biotechnologies Gmbh | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| GB201006360D0 (en) | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| US20140170168A1 (en) | 2010-10-26 | 2014-06-19 | Yoram Reiter | Antibodies which bind soluble t-cell receptor ligands |
| WO2013057586A1 (en) | 2011-10-19 | 2013-04-25 | Oslo Universitetssykehus Hf | Compositions and methods for producing soluble t - cell receptors |
| ES2603589T3 (es) | 2012-11-08 | 2017-02-28 | F. Hoffmann-La Roche Ag | Ácidos nucleicos que codifican polipéptidos quiméricos para la identificación sistemática de bibliotecas |
| EP2808392A1 (en) | 2013-05-28 | 2014-12-03 | Rheinische Friedrich-Wilhelms-Universität Bonn | Aptamers and use of the aptamers in the diagnosis and treatment of cancer |
| TWI777197B (zh) * | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（六） |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| GB201411037D0 (en) * | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| MA41218A (fr) * | 2014-12-19 | 2017-10-24 | Advaxis Inc | Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| WO2016172722A1 (en) * | 2015-04-23 | 2016-10-27 | Nantomics, Llc | Cancer neoepitopes |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| GB201517538D0 (en) | 2015-10-05 | 2015-11-18 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers |
| GB201520583D0 (en) | 2015-11-23 | 2016-01-06 | Immunocore Ltd & Adaptimmune Ltd | Peptides |
| WO2017089786A1 (en) | 2015-11-23 | 2017-06-01 | Immunocore Limited | Peptides |
| ES2975747T3 (es) * | 2015-11-30 | 2024-07-12 | Univ California | Administración de carga útil específica de tumor y activación inmunitaria utilizando un anticuerpo humano que se dirige a un antígeno de superficie celular de tumor altamente específico |
| ES3013993T3 (en) | 2017-07-04 | 2025-04-16 | CureVac SE | Cancer rna-vaccine |
| CN111886027B (zh) * | 2017-12-28 | 2025-06-24 | 磨石生物公司 | 靶向共同抗原的抗原结合蛋白 |
-
2018
- 2018-07-09 US US16/030,725 patent/US10925947B2/en not_active Expired - Fee Related
-
2019
- 2019-06-19 US US16/446,384 patent/US10946081B2/en not_active Expired - Fee Related
- 2019-06-19 CN CN201980044402.2A patent/CN112399853A/zh active Pending
- 2019-06-19 CA CA3097698A patent/CA3097698A1/en active Pending
- 2019-06-19 WO PCT/EP2019/066115 patent/WO2020002063A1/en not_active Ceased
- 2019-06-19 AU AU2019294731A patent/AU2019294731A1/en not_active Abandoned
- 2019-06-19 JP JP2020560739A patent/JP7579145B2/ja active Active
- 2019-06-19 CR CR20200632A patent/CR20200632A/es unknown
- 2019-06-19 SG SG11202009659XA patent/SG11202009659XA/en unknown
- 2019-06-19 CN CN202110718511.7A patent/CN113444148A/zh active Pending
- 2019-06-19 BR BR112020022250-0A patent/BR112020022250A2/pt unknown
- 2019-06-19 EP EP19733696.9A patent/EP3813873A1/en not_active Withdrawn
- 2019-06-19 MX MX2020012257A patent/MX2020012257A/es unknown
- 2019-06-19 MA MA053004A patent/MA53004A/fr unknown
- 2019-06-19 PE PE2020002193A patent/PE20211499A1/es unknown
- 2019-06-19 KR KR1020207037583A patent/KR20210025534A/ko not_active Ceased
- 2019-06-28 TW TW108122776A patent/TW202019462A/zh unknown
-
2020
- 2020-05-29 US US16/887,815 patent/US10828357B2/en not_active Expired - Fee Related
- 2020-06-30 US US16/917,381 patent/US10869917B2/en not_active Expired - Fee Related
- 2020-10-29 CO CONC2020/0013659A patent/CO2020013659A2/es unknown
- 2020-11-24 PH PH12020552013A patent/PH12020552013A1/en unknown
- 2020-12-23 CL CL2020003371A patent/CL2020003371A1/es unknown
- 2020-12-29 IL IL279843A patent/IL279843A/en unknown
-
2021
- 2021-01-14 US US17/149,241 patent/US11833193B2/en active Active
- 2021-01-14 US US17/149,381 patent/US11058755B2/en not_active Expired - Fee Related
- 2021-01-14 US US17/149,397 patent/US11872270B2/en active Active
- 2021-07-02 US US17/366,958 patent/US11246917B2/en active Active
- 2021-07-02 US US17/366,885 patent/US12076379B2/en active Active
-
2022
- 2022-07-19 US US17/868,368 patent/US11554164B2/en active Active
- 2022-07-29 US US17/876,899 patent/US11576955B2/en active Active
- 2022-11-30 CL CL2022003380A patent/CL2022003380A1/es unknown
- 2022-11-30 CL CL2022003382A patent/CL2022003382A1/es unknown
- 2022-11-30 CL CL2022003381A patent/CL2022003381A1/es unknown
-
2023
- 2023-01-27 US US18/160,420 patent/US20230226162A1/en active Pending
-
2024
- 2024-10-23 JP JP2024186997A patent/JP2025013943A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002459A1 (es) | Péptidos y combinaciones de péptidos para uso en inmunoterapia contra el cáncer (divisional de la solicitud no. 201902093) | |
| CL2021000841A1 (es) | Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer. (divisional de la solicitud no. 202002123) | |
| CR20200560A (es) | PÉPTIDOS Y COMBINACIONES DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL LINFOMA NO HADGKINIANO (LNH) Y OTROS TIPOS DE CÁNCER (Divisional 2018-0346) | |
| CO2019012077A2 (es) | Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer | |
| CO2021000534A2 (es) | Inmunoterapia con péptidos restringidos a b*07 y una combinación de péptidos contra el cáncer y métodos relacionados | |
| CO2021004270A2 (es) | Péptidos restringidos por b*44 para el uso en la inmunoterapia contra el cáncer y métodos relacionados | |
| CR20200639A (es) | NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS COMO DIANAS Y PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE VESÍCULA BILIAR Y EL COLANGIOCARCINOMA, ASÍ COMO OTROS TIPOS DE CÁNCER (Divisional 2018-0591) | |
| CL2022003380A1 (es) | Péptidos restringidos por a*03, uso en inmunoterapia contra cáncer y métodos relacionados (solicitud divisional de 202003371) | |
| CO2021003404A2 (es) | Inmunoterapia con péptidos restringidos a a*01 y una combinación de péptidos contra el cáncer y métodos relacionados | |
| CO2020013652A2 (es) | Péptidos para el uso en la inmunoterapia contra el cáncer | |
| CL2021000177A1 (es) | Péptidos, combinaciones de péptidos, células y kits para el uso en la inmunoterapia contra el cáncer (divisional de la solicitud no. 201802360) | |
| CL2021001336A1 (es) | Inmunoterapia con péptidos restringidos a b*08 y una combinación de péptidos contra el cáncer y métodos relacionados | |
| CL2021001525A1 (es) | Nuevos péptidos y nueva combinación de péptidos como dianas y para el uso en la inmunoterapia contra el cáncer de vesícula biliar y el colangiocarcinoma, así como otros tipos de cáncer (divisional de la solicitud no. 201803293) | |
| AR114736A1 (es) | Péptidos restringidos por b*44 para el uso en la inmunoterapia contra el cáncer y métodos relacionados | |
| AR117437A1 (es) | Inmunoterapia con péptidos restringidos a b*08 y una combinación de péptidos contra el cáncer y métodos relacionados | |
| AR115881A1 (es) | Inmunoterapia con péptidos restringidos a b*07 y una combinación de péptidos contra el cáncer y métodos relacionados | |
| AR114532A1 (es) | Péptidos para el uso en la inmunoterapia contra el cáncer | |
| AR115254A1 (es) | Péptidos y combinación de péptidos de origen no canónico para el uso en la inmunoterapia contra diferentes tipos de cáncer |